
Celemics
Celemics is a genomics company founded in 2010 and headquartered in Seoul, Korea, with a U.S. office in California. Celemics designs the hybrid-capture panels and target-enrichment chemistry behind our oncology NGS portfolio, and AchieveDx runs the testing and reporting. Our PGx testing is separate and is not a Celemics product.
- Proprietary probe-synthesis technology for hybrid-capture target enrichment
- More than 10 years designing and customizing NGS panels
- ctDNA panels developed with Seoul National University Hospital since 2017
- Publicly listed genomics company (KOSDAQ)

